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SUMMARY POINTS
● The rapid and continuing progress in gene discovery for
complex diseases is fueling interest in the potential appli-
cation of genetic risk models for clinical and public health
practice.
● The number of studies assessing the predictive ability is
steadily increasing, but the quality and completeness of
reporting varies.
● A multidisciplinary workshop sponsored by the Human
Genome Epidemiology Network developed a checklist of
25 items recommended for strengthening the reporting of
Genetic RIsk Prediction Studies (GRIPS), building on the
principles established by prior reporting guidelines.
● These recommendations aim to enhance the transparency
of study reporting, and thereby to improve the synthesis
and application of information from multiple studies that
might differ in design, conduct, or analysis.
● A detailed Explanation and Elaboration document
is published as Supplemental Digital Content 1,
http://links.lww.com/GIM/A165.
INTRODUCTION
The recent successes of genome-wide association studies and
the promises of whole genome sequencing fuel interest in the
translation of this new wave of basic genetic knowledge to
health care practice. Knowledge about genetic risk factors may
be used to target diagnostic, preventive, and therapeutic inter-
ventions for complex disorders based on a person’s genetic risk,
or to complement existing risk models based on classical non-
genetic factors such as the Framingham risk score for cardio-
vascular disease. Implementation of genetic risk prediction in
health care requires a series of studies that encompass all phases
of translational research,1,2 starting with a comprehensive eval-
uation of genetic risk prediction.
With increasing numbers of discovered genetic markers that
can be used in future genetic risk prediction studies, it is crucial
to enhance the quality of the reporting of these studies, since
valid interpretation could be compromised by the lack of re-
porting of key information. Information that is often missing
includes details in the description of how the study was de-
signed and conducted (e.g., how genetic variants were selected
and coded, how risk models or genetic risk scores were con-
structed, and how risk categories were chosen), or how the
results should be interpreted. An appropriate assessment of the
study’s strengths and weaknesses is not possible without this
information. There is ample evidence that prediction research
often suffers from poor design and bias, and these may also
have an impact on the results of the studies and on models of
disease outcomes based on these studies.3–5 Although most
prognostic studies published to date claim significant results,6,7
very few translate to clinically useful applications. Just as for
observational epidemiological studies,8 poor reporting compli-
cates the use of the specific study for research, clinical, or public
health purposes and hampers the synthesis of evidence across
studies.
Reporting guidelines have been published for various re-
search designs,9 and these contain many items that are also
relevant to genetic risk prediction studies. In particular, the
guidelines for genetic association studies (STrengthening the
REporting of Genetic Association studies [STREGA]) have
relevant items on the assessment of genetic variants, and the
guidelines for observational studies (Strengthening the Report-
ing of OBservational studies in Epidemiology [STROBE]) have
relevant items about the reporting of study design. The guide-
lines for diagnostic studies (STAndards for Reporting Diagnos-
tic accuracy [STARD]) and those for tumor marker prognostic
studies (Guidelines for Reporting of tumor MARKer studies
[REMARK]) include relevant items about test evaluation; the
REMARK guidelines also have relevant items about risk pre-
diction.10–13 However, none of these guidelines are fully suited
to genetic risk prediction studies, an emerging field of investi-
gation with specific methodological issues that need to be
addressed, such as the handling of large numbers of genetic
variants (from 10s to 10,000s) and flexibility in handling such
large numbers in analyses. We organized a two-day workshop
with an international group of risk prediction researchers, epi-
demiologists, geneticists, methodologists, statisticians, and
journal editors to develop recommendations for the reporting of
Genetic RIsk Prediction Studies (GRIPS).
GENETIC RISK PREDICTION STUDIES
Genetic risk prediction studies typically develop or validate
models that predict the risk of disease, but they are also being
investigated for use in predicting prognostic outcome, treatment
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response, or treatment-related harms. Risk prediction models
are statistical algorithms, which may be simple genetic risk
scores (e.g., risk allele counts), may be based on regression
analyses (e.g., weighted risk scores or predicted risks), or may
be based on more complex analytic approaches such as support
vector machine learning or classification trees. The risk models
may be based on genetic variants only, or include both genetic
and nongenetic risk factors.14
AIMS AND USE OF THE GRIPS STATEMENT
The 25 items of the GRIPS statement are intended to maxi-
mize the transparency, quality, and completeness of reporting
on research methodology and findings in a particular study. It is
important to emphasize that these recommendations are guide-
lines only for how to report research and do not prescribe how
to perform genetic risk prediction studies. The guidelines do not
support or oppose the choice of any particular study design or
method, e.g., the guidelines recommend that the study popula-
tion should be described, but do not specify which population is
preferred in a particular study.
The intended audience for the reporting guidelines is broad and
includes epidemiologists, geneticists, statisticians, clinician scien-
tists, and laboratory-based investigators who undertake genetic risk
prediction studies, as well as journal editors and reviewers who
have to appraise the design, conduct and analysis of such studies.
In addition, it includes “users” of such studies who wish to under-
stand the basic premise, design, and limitations of genetic predic-
tion studies in order to interpret the results for their potential
application in health care. These guidelines are also intended to
ensure that essential data from future genetic risk prediction studies
are presented in standardized form, which will facilitate informa-
tion synthesis as part of systematic reviews and meta-analyses.
Items presented in the checklist are relevant for a wide array of
risk prediction studies, because GRIPS focuses on the main aspects
of the design and analysis of risk prediction studies. GRIPS does
not address randomized trials that may be performed to test risk
models, nor does it specifically address decision analyses, cost-
effectiveness analyses, assessment of health care needs, or assess-
ment of barriers to health care implementation.15 Once the perfor-
mance of a risk model has been established, these next steps toward
implementation require further evaluation.10,16 For the reporting of
these studies, which go beyond the assessment of genetic risk
models as such, additional requirements apply. However, proper
documentation of genetic predictive research according to GRIPS
might facilitate the translation of research findings into clinical and
public health practice.
DEVELOPMENT OF THE GRIPS STATEMENT
The GRIPS statement was developed by a multidisciplinary
panel of 25 risk prediction researchers, epidemiologists, genet-
icists, methodologists, statisticians, and journal editors, seven of
whom were also part of the STREGA initiative.11 They attended
a two-day meeting in Atlanta, Georgia (US) in December 2009
that was sponsored by the US Centers for Disease Control and
Prevention on behalf of the Human Genome Epidemiology
Network (HuGENet).17 Participants discussed a draft version of
the guidelines that was prepared and distributed before the
meeting. This draft version was developed on the basis of
existing reporting guidelines, namely STREGA,11 REMARK,13
and STARD.12 These were selected out of all available guide-
lines (see http://www.equator-network.org) because of their fo-
cus on observational study designs and genetic factors
(STREGA), prediction models (REMARK), and test evaluation
(REMARK and STARD). During the meeting, methodological
issues pertinent to risk prediction studies were addressed in
presentations. Workshop participants were asked to change,
combine, or delete proposed items and add additional items if
necessary. Participants had extensive post-meeting electronic
correspondence. To harmonize our recommendations for ge-
netic risk prediction studies with previous guidelines, we chose
the same wording for the items wherever possible. Finally, we
tried to create consistency with previous guidelines for the
evaluation of risk prediction studies of cardiovascular diseases
and cancer.2,18 The final version of the checklist is presented in
Table 1.
THE GRIPS EXPLANATION AND ELABORATION
ARTICLE
Accompanying this GRIPS statement, an Explanation and
Elaboration document has been written (see Supplemental Dig-
ital Content 1, http://links.lww.com/GIM/A165), modeled after
those developed for other reporting guidelines.19–22 The Expla-
nation and Elaboration document illustrates each item with at
least one published example that we consider transparent in
reporting, explains the rationale for its inclusion in the checklist,
and presents details of the items that need to be addressed to
ensure transparent reporting. The Explanation and Elaboration
document was produced after the meeting (Supplemental Dig-
ital Content 1, http://links.lww.com/GIM/A165). The document
was prepared by a small subgroup and shared with all workshop
participants for additional revisions and final approval.
CONCLUDING REMARKS AND FUTURE
DIRECTIONS
High-quality reporting reveals the strengths and weaknesses
of empirical studies, facilitates the interpretation of the scientific
and health care relevance of the results—especially within the
framework of systematic reviews and meta-analyses—and helps
build a solid evidence base for moving genomic discoveries into
applications in health care practice. The GRIPS guidelines were
developed to improve the transparency, quality and complete-
ness of the reporting of genetic risk prediction studies. As
outlined in the introduction, GRIPS does not prescribe how
studies should be designed, conducted, or analyzed, and there-
fore the guidelines should not be used to assess the quality of
empirical studies.23 The guidelines should be used only to check
whether all essential items are adequately reported.
Finally, the methodology for designing and assessing genetic
risk prediction models is still developing. For example, newer
measures of reclassification were first introduced in 2007,24 and
several alternative reclassification measures have been pro-
posed.25 Which measures to apply and when to use measures of
reclassification are still subject to ongoing evaluation and dis-
cussion.26 Furthermore, alternative strategies for constructing
risk models other than simple regression analyses are being
explored, and these may add increased complexity to the re-
porting. In formulating the items of the GRIPS statement, these
methodological advances were anticipated. It is for this reason
that the GRIPS statement recommends how a study should be
reported and not how a study should be conducted or analyzed.
Therefore, methodological and analytical developments will not
immediately impact the validity and relevance of the items, but
the GRIPS statement will be updated when this is warranted by
essential new developments in the construction and evaluation
of genetic risk models.
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Table 1 Reporting recommendations for evaluations of risk prediction models that include genetic variants
TITLE & ABSTRACT
1 (a) Identify the article as a study of risk prediction using genetic factors. (b) Use recommended keywords in
the abstract: genetic or genomic, risk, prediction.
INTRODUCTION
Background and rationale 2 Explain the scientific background and rationale for the prediction study.
Objectives 3 Specify the study objectives and state the specific model(s) that is/are investigated. State if the study
concerns the development of the model(s), a validation effort, or both.
METHODS
Study design and setting 4* Specify the key elements of the study design and describe the setting, locations, and relevant dates, including
periods of recruitment, follow-up, and data collection.
Participants 5* Describe eligibility criteria for participants, and sources and methods of selection of participants.
Variables: Definition 6* Clearly define all participant characteristics, risk factors and outcomes. Clearly define genetic variants using
a widely-used nomenclature system.
Variables: Assessment 7* (a) Describe sources of data and details of methods of assessment (measurement) for each variable. (b) Give
a detailed description of genotyping and other laboratory methods.
Variables: Coding 8 (a) Describe how genetic variants were handled in the analyses. (b) Explain how other quantitative variables
were handled in the analyses. If applicable, describe which groupings were chosen, and why.
Analysis: Risk model
construction
9 Specify the procedure and data used for the derivation of the risk model. Specify which candidate variables
were initially examined or considered for inclusion in models. Include details of any variable selection
procedures and other model-building issues. Specify the horizon of risk prediction (e.g., 5-year risk).
Analysis: Validation 10 Specify the procedure and data used for the validation of the risk model.
Analysis: Missing data 11 Specify how missing data were handled.
Analysis: Statistical
methods
12 Specify all measures used for the evaluation of the risk model including, but not limited to, measures of
model fit and predictive ability.
Analysis: Other 13 Describe all subgroups, interactions, and exploratory analyses that were examined.
RESULTS
Participants 14* Report the numbers of individuals at each stage of the study. Give reasons for nonparticipation at each stage.
Report the number of participants not genotyped, and reasons why they were not genotyped.
Descriptives: Population 15* Report demographic and clinical characteristics of the study population, including risk factors used in the
risk modeling.
Descriptives: Model
estimates
16 Report unadjusted associations between the variables in the risk model(s) and the outcome. Report adjusted
estimates and their precision from the full risk model(s) for each variable.
Risk distributions 17* Report distributions of predicted risks and/or risk scores.
Assessment 18 Report measures of model fit and predictive ability, and any other performance measures, if pertinent.
Validation 19 Report any validation of the risk model(s).
Other analyses 20 Present results of any subgroup, interaction, or exploratory analyses, whenever pertinent.
DISCUSSION
Limitations 21 Discuss limitations and assumptions of the study, particularly those concerning study design, selection of
participants, and measurements and analyses, and discuss their impact on the results of the study.
Interpretation 22 Give an overall interpretation of results considering objectives, limitations, multiplicity of analyses, results
from similar studies, and other relevant evidence.
Generalizability 23 Discuss the generalizability and, if pertinent, the health care relevance of the study results.
OTHER
Supplementary
information
24 State whether databases for the analyzed data, risk models, and/or protocols are or will become publicly
available and if so, how they can be accessed.
Funding 25 Give the source of funding and the role of the funders for the present study. State whether there are any
conflicts of interest.
*Marked items should be reported for every population in the study.
Genetics IN Medicine • Volume 13, Number 5, May 2011 Psychosocial impact of genetic information on children
Genetics IN Medicine • Volume 13, Number 5, May 2011 455
ACKNOWLEDGMENTS
The members of the GRIPS group are: A. Cecile J. W.
Janssens, John P. A. Ioannidis, Sara Bedrosian, Paolo Boffetta,
Siobhan M. Dolan, Nicole Dowling, Isabel Fortier, Andrew N.
Freedman, Jeremy M. Grimshaw, Jeffrey Gulcher, Marta
Gwinn, Mark A. Hlatky, Holly Janes, Peter Kraft, Stephanie
Melillo, Christopher J. O’Donnell, Michael J. Pencina, David
Ransohoff, Sheri D. Schully, Daniela Seminara, Deborah M.
Winn, Caroline F. Wright, Cornelia M. van Duijn, Julian Little,
and Muin J. Khoury.
Copyright: © 2011 Janssens et al. This is an open-access
article distributed under the terms of the Creative Commons
Attribution License, which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided the original
author and source are credited.
Funding: Workshop was sponsored by the Centers for Dis-
ease Control and Prevention on behalf of the Human Genome
Epidemiology Network (HuGENet). The findings and conclu-
sions in this report are those of the authors and do not neces-
sarily reflect the views of the Department of Health and Human
Services. A. Cecile J.W. Janssens is financially supported by
grants from the Erasmus University Medical Center Rotterdam,
the Center for Medical Systems Biology in the framework of the
Netherlands Genomics Initiative (NGI) and the VIDI grant of
the Netherlands Organisation for Scientific Research (NWO).
John P.A. Ioannidis: Tufts CTSI is supported by the National
Institutes of Health/National Center for Research Resources
(UL1 RR025752). Opinions in this paper are those of the
authors and do not necessarily represent the official position or
policies of the Tufts CTSI. Julian Little holds a Canada Re-
search Chair in Human Genome Epidemiology. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: John Ioannidis is a member of the
PLoS Medicine Editorial Board.
Provenance: Not commissioned; externally peer reviewed.
In order to encourage dissemination of the GRIPS Statement, this
article will also be published by Annals of Internal Medicine, BMJ,
Circulation: Cardiovascular Genetics, European Journal of Clin-
ical Investigation, European Journal of Epidemiology, European
Journal of Human Genetics, Genetics in Medicine, Genome Med-
icine, and Journal of Clinical Epidemiology.
REFERENCES
1. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, et al. The
continuum of translation research in genomic medicine: how can we accel-
erate the appropriate integration of human genome discoveries into health
care and disease prevention? Genet Med 2007;9:665–674.
2. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, et al.
Criteria for evaluation of novel markers of cardiovascular risk: a scientific
statement from the American Heart Association. Circulation 2009;119:2408–
2416.
3. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Quality of reporting of cancer
prognostic marker studies: association with reported prognostic effect. J Natl
Cancer Inst 2007;99:236–243.
4. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer
prognostic factor studies. J Natl Cancer Inst 2005;97:1043–1055.
5. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. REporting
recommendations for tumor MARKer prognostic studies (REMARK). Nat
Clin Pract Urol 2005;2:416–422.
6. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer
prognostic markers report statistically significant results. Eur J Cancer 2007;
43: 2559–2579.
7. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved
prediction beyond the Framingham risk score. JAMA 2009;302:2345–2352.
8. von Elm E, Egger M. The scandal of poor epidemiological research. BMJ
2004;329:868–869.
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting
guidelines for health research. Eur J Clin Invest 2010;40:35–53.
10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, et al. The
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) statement: guidelines for reporting observational studies. PLoS
Med 2007;4:e296.
11. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. STrengthening
the REporting of Genetic Association Studies (STREGA): an extension of the
STROBE statement. PLoS Med 2009;6:e22.
12. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al.
Towards complete and accurate reporting of studies of diagnostic accuracy:
the STARD initiative. BMJ 2003;326:41–44.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. Reporting
recommendations for tumor marker prognostic studies. J Clin Oncol 2005;
23:9067–9072.
14. Janssens ACJW, Van Duijn CM. Genome-based prediction of common dis-
eases: methodological considerations for future research. Genome Med 2009;
1:20.
15. Khoury MJ, Gwinn M, Ioannidis JP. The emergence of translational epide-
miology: from scientific discovery to population health impact. Am J Epide-
miol 2010;172:517–524.
16. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic
research: application and impact of prognostic models in clinical practice.
BMJ 2009;338:b606.
17. Khoury MJ, Dorman JS. The Human Genome Epidemiology Network. Am J
Epidemiol 1998;148:1–3.
18. Freedman AN, Seminara D, Gail MH, Hartge P, Colditz GA, et al. Cancer risk
prediction models: a workshop on development, evaluation, and application.
J Natl Cancer Inst 2005;97:715–723.
19. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, et al. The revised
CONSORT statement for reporting randomized trials: explanation and elab-
oration. Ann Intern Med 2001;134:663–694.
20. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. The
STARD statement for reporting studies of diagnostic accuracy: explanation
and elaboration. Ann Intern Med 2003;138:W1–W12.
21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. The
PRISMA statement for reporting systematic reviews and meta-analyses of
studies that evaluate health care interventions: explanation and elaboration.
PLoS Med 2009;6:e1000100.
22. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, et al.
Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE): explanation and elaboration. PLoS Med 2007;4:e297.
23. Vandenbroucke JP. STREGA, STROBE, STARD, SQUIRE, MOOSE,
PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK . . .
and CONSORT: for whom does the guideline toll? J Clin Epidemiol 2009;
62:594–596.
24. Cook NR. Use and misuse of the receiver operating characteristic curve in risk
prediction. Circulation 2007;115:928–935.
25. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the
added predictive ability of a new marker: from area under the ROC curve to
reclassification and beyond. Stat Med 2008;27:157–172.
26. Janssens ACJW, Khoury MJ. Assessment of improved prediction beyond
traditional risk factors: when does a difference make a difference? Circ:
Cardiovasc Genet 2010;3:3–5.
Janssens et al. Genetics IN Medicine • Volume 13, Number 5, May 2011
456 © 2011 Lippincott Williams & Wilkins
